Atezolizumab, bevacizumab, pemetrexed and platinum for <i>EGFR</i>‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
Shang‐Gin Wu(National Taiwan University), Jin‐Yuan Shih(National Taiwan University Hospital)
Cited by 9
Related Papers
EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway
|Scientific Reports|2015|69
Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer
|International Journal of Cancer|2019|61
Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
|PLoS ONE|2011|49
miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44
|Molecular Therapy — Nucleic Acids|2023|18